Search

773 Result(s)
Sort by

Dominik Huber

Dominik Huber

Dominik Huber, Our Head of Upstream Manufacturing in Vienna, Dominik Huber, has built his entire, senior-level career with Boehringer Ingelheim.
Vaccine prevent calf diarrhea

Vaccine prevent calf diarrhea

Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus
Partnership canine oncology

Partnership canine oncology

The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Facing lung cancer

Facing lung cancer

Keith and Heather talk about their experiences of facing lung cancer as a family and finding purpose after treatment.
Dogs at work in Milan offices

Dogs at work in Milan offices

Dogs at work is a pilot project that allows pet-lover to bring their dogs to the office and enjoy the benefits they bring to their daily work life.
Pascal Haubert

Pascal Haubert

Three months into an internship with us, Pascal Haubert talks about responsibility, learning, and mutual support.
Yanina Donatini

Yanina Donatini

Yanina Donatini, Head of ITM&S Content Production, jumped at the chance to fulfill her dreams within the Information Technology division at Boehringer Ingelheim.
Albert Paul

Albert Paul

Albert Paul: driven to make a difference
Bok Oh

Bok Oh

Touching millions of lives with Bok Oh
Living with heart failure

Living with heart failure

Hear Patricia’s story on the impact that heart failure can have on mental health and the importance of finding support networks.
Systemic sclerosis physician video

Systemic sclerosis physician video

In this video Professor Chris Denton (Consultant Rheumatologist) discusses his experience diagnosing systemic sclerosis, also known as scleroderma
Production Insights

Production Insights

Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals
Boehringer Ingelheim acquires Nerio Therapeutics

Boehringer Ingelheim acquires Nerio Therapeutics

Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics